C.M. Bidwell & Associates’s RxSight RXST Stock Holding History

C.M. Bidwell & Associates’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8	Closed	-$395	–	531
2024 Q3	$395	Buy	+8	New	+$410	﹤0.01%	479

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

C.M. Bidwell & Associates's RXST Position: Q4 2024 in Review

C.M. Bidwell & Associates sold out of RxSight (RXST) in Q4 2024, closing a stake of 8 shares — an estimated $395 sold.

C.M. Bidwell & Associates first reported a position in RXST in Q3 2024 and held it in 1 quarter. The position peaked at $395 in Q3 2024. 212 funds tracked by Wall St. Rank hold RXST as of Q4 2024.

C.M. Bidwell & Associates reported no remaining RxSight position as of Q4 2024 after selling out during the quarter.
C.M. Bidwell & Associates sold 8 RxSight shares in Q4 2024, an estimated $395.
C.M. Bidwell & Associates first reported a position in RxSight in Q3 2024 and held it in 1 quarter.
C.M. Bidwell & Associates's RxSight position peaked at $395 in Q3 2024.
212 funds tracked by Wall St. Rank held RxSight as of Q4 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2024, filed 12 Feb 2025.